Overview

This trial is active, not recruiting.

Conditions growth hormone treatment, glaucoma
Treatment measuring intraoccular pressure
Sponsor Assaf-Harofeh Medical Center
Start date February 2009
End date October 2010
Trial size 100 participants
Trial identifier NCT00867971, 162/08

Summary

Recombinant growth hormone is a common therapy in the pediatric population. A number of associated side effects have been described. Several years ago, a case report was published concerning a child that was treated with RGH and developed acute glaucoma. To date no study has evaluated the connection.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional
Arm
measuring intraoccular pressure
Measurement of intraoccular pressure by tonometry
measuring intraoccular pressure
Measurement of intraoccular pressure by tonometry

Primary Outcomes

Measure
Intraoccular pressure in children treated with RGH
time frame: 2 years

Eligibility Criteria

Male or female participants from 6 years up to 18 years old.

Inclusion Criteria: - Age 6-18 years - treatment with recombinant growth hormone Exclusion Criteria: - Underlying Chronic diseases - Family history of eye diseases - elevated occular pressure prior to starting treatment

Trial information was received from ClinicalTrials.gov and was last updated in March 2009.
Information provided to ClinicalTrials.gov by Assaf-Harofeh Medical Center.